SCHEMBL855469

SCHEMBL855469

O=C1NC(=O)C(COC(=O)C(Cl)(Cl)Cl)N1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.35
ADAMTS5 Q9UNA0 9/20 0.33
ADAM17 P78536 2/20 0.33
ADAMTS4 O75173 2/20 0.33
ADAM10 O14672 1/20 0.33
MMP12 P39900 1/20 0.33
ADAM9 Q13443 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
CASP1 P29466 1/20 0.33
TSHR P16473 2/20 0.32
RGS12 O14924 1/20 0.32
MMP2 P08253 1/20 0.32
HTT P42858 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL855440 0.78 GAA (0.38) GAASMN1; SMN2ADAMTS5ADAM17ADAMTS4
SCHEMBL27610704 0.77 SMN1; SMN2 (0.41) GAASMN1; SMN2ADAMTS5ADAM17ADAMTS4
SCHEMBL18007465 0.76 GAA (0.39) GAASMN1; SMN2ADAMTS5ADAM17ADAMTS4
SCHEMBL18007464 0.76 GAA (0.39) GAASMN1; SMN2ADAMTS5ADAM17ADAMTS4
SCHEMBL17966450 0.72 HCAR2 (0.42) GAASMN1; SMN2ADAMTS5ADAMTS4ALDH1A1
SCHEMBL853707 0.70 GAA (0.37) GAAADAMTS5ADAM17ADAMTS4ADAM10
SCHEMBL18009095 0.70 HTT (0.34) GAASMN1; SMN2ALDH1A1HTT
SCHEMBL18009125 0.70 HCAR2 (0.39) GAASMN1; SMN2ADAMTS5ADAM17ALDH1A1
SCHEMBL8402767 0.69 ESR1 (0.46) GAASMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL1011631 0.69 TSHR (0.43) GAASMN1; SMN2ADAMTS5ADAM17ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420683-B2 5 substituted hydantoins DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2013-04-16 US disclosed
EP-2150538-B1 NOVEL 5-SUBSTITUTED HYDANTOINS DSM SINOCHEM PHARM NL BV (NL) 2012-03-28 EP disclosed
US-20100174092-A1 NOVEL 5 SUBSTITUTED HYDANTOINS DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2010-07-08 US disclosed
EP-2150538-A2 NOVEL 5-SUBSTITUTED HYDANTOINS DSM IP Assets B.V. (NL) 2010-02-10 EP disclosed
WO-2008148755-A2 NOVEL 5-SUBSTITUTED HYDANTOINS DSM IP ASSETS B.V. (NL) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100174092-A1 NOVEL 5 SUBSTITUTED HYDANTOINS CYP3A5, REN, ACE GAA 2157/4885SMN1; SMN2 4431/4885ADAMTS5 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.